Malte von Bonin

CD19 CAR-T therapy induces remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid syndrome

Isabel K. Korte, Soraya Kharboutli, Simon Völkl, Lisa Heberling et autres

de (code pays fourni par la source)

Teclistamab interference with anti-BCMA chimeric antigen receptor T-cell detection by flow cytometry: duration and clinical implications

Jonas Schadt, Malte von Bonin, Uta Oelschlägel, Raphael Teipel et autres

Teclistamab is a bi-specific antibody targeting CD3 and B-cell maturation antigen (BCMA), used in relapsed or refractory multiple myeloma (MM) beyond first-line therapy. Even though it achieves response rates of up to 63% [ 1 ], relapses are common with a median …

de (code pays fourni par la source)

Comparison of deep-learning-based delineation of lymphoma lesions in [18F]FDG PET and PET/CT images

Pavel Nikulin, Sebastian Hoberück, F Hofheinz, A Hüttmann et autres

Ziel/Aim: Delineation of all tumor lesions in PET images of lymphoma patients is required for extraction of prognostic biomarkers. Since this process is time-consuming and non-trivial with classical approaches, the deep-learning-based delineation represents a promising alternative. While the majority of deep-learning models …

de (code pays fourni par la source)

Impact of small lesions on the prognostic value of TMTV in patientswith diffuse large B-cell lymphoma

Frank Hofheinz, Pavel Nikulin, Jens Maus, A Hüttmann et autres

Ziel/Aim: It was shown in several investigations that the total metabolic tumor volume (TMTV), determined in [F-18]FDG PET, has a high prognostic value in patients with diffuse large B-cell lymphoma (DLBCL). However, in most of these studies, small lesions (<3ml) were excluded …

de (code pays fourni par la source)

A convolutional neural network for fully automated total metabolic tumor volume delineation in patients with aggressive Non-Hodgkin lymphoma

Pavel Nikulin, Sebastian Hoberück, Ivayla Apostolova, Jens Maus et autres

PURPOSE: The [18F]FDG-PET-derived total metabolic tumor volume (TMTV) has a high prognostic value in patients with Hodgkin and Non-Hodgkin lymphoma. However, in order to enable TMTV as a biomarker for clinical use, an accurate and fast method of tumor delineation in lymphoma …

de (code pays fourni par la source)

Steady‐state mobilization with on‐demand plerixafor after CD38 antibody‐based induction in multiple myeloma patients

Maximilian Alexander Röhnert, Anna Seifert, Karolin Trautmann‐Grill, Christoph Röllig et autres

Abstract Background High‐dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for fit patients with newly diagnosed multiple myeloma (MM). The increasing use of CD38 antibody‐based quadruplet induction regimens such as daratumumab‐VTd (Dara‐VTd) has raised concerns regarding …

de (code pays fourni par la source)

Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial

Leo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, Matthias Stelljes et autres

Background Patients with relapsed or refractory acute myeloid leukaemia have a poor prognosis. Outcomes with conventional intensive salvage chemotherapy are suboptimal. We aimed to evaluate the safety and activity of high-dose cytarabine and mitoxantrone in combination with venetoclax in patients with relapsed …

de (code pays fourni par la source)

Measurable residual disease by multicolor flow cytometry in acute myeloid leukemia: A comparison of peripheral blood and bone marrow

Jonas Schadt, Malte von Bonin, Uta Oelschlägel, Christoph Röllig et autres

Abstract Measurable residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) is well established in bone marrow (BM) samples for acute myeloid leukemia (AML), but its use in peripheral blood (PB) remains less developed. We adapted a semi‐automated and well validated MFC‐MRD …

de (code pays fourni par la source)

Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland

Linda Simon, Vladan Vucinic, Kai Rejeski, Maria‐Luisa Schubert et autres

Mantle Cell Lymphoma (MCL) is an incurable B-cell neoplasm, representing 6–8% of newly diagnosed B-cell lymphomas [ 1 ]. Brexucabtagene-autoleucel (brexu-cel, Tecartus®) is a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy approved in Europe for treatment of relapsed/refractory (r/r) MCL after two …

de, ch, us, fr (code pays fourni par la source)

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

Anne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, Katja Sockel et autres

ABSTRACT: Measurable residual disease (MRD) can predict relapse in patients with advanced myelodysplastic neoplasms (MDS) or acute myeloid leukemia (AML). We report the long-term efficacy and safety of MRD-guided preemptive azacitidine treatment to prevent relapse in the phase 2 Relapse Prevention With …

de, at, us (code pays fourni par la source)

LyROI – nnU-Net-based Lymphoma Total Metabolic Tumor Volume Delineation

Pavel Nikulin, Sebastian Hoberück, Ivayla Apostolova, Jens Maus et autres

Collection of neural network models for metabolic tumor volume delineation in (Non-Hodgkin) lymphoma patients in FDG-PET/CT images. Intended to use within nnU-Net deep learning framework. Trained with a total of 1192 [18F]FDG-PET/CT scans from 716 patients with Non-Hodgkin lymphoma participating in the …

de (code pays fourni par la source)

The long non-coding RNA WT1-AS controls differentiation programs and leukemic cell fate in AML

Silvia Schäfer, Pascal Fichtel, Silke Brilloff, Elahe Rahimian et autres

Abstract Therapy of AML patients remains challenging due to high rates of relapses even after intensive treatment. Relapses are mostly caused by residual chemoresistant leukemic stem cells (LSC). Long non-coding RNAs (lncRNA) have been shown to be important regulators of normal hematopoiesis …

de, us (code pays fourni par la source)